Suit alleges The Chemours Company failed to disclose key facts to investors from February 20, 2026 through August 4, 2026; lead plaintiff deadline is December 7, 2026
BENSALEM TOWNSHIP, Pa., Oct. 20, 2026 /PRNewswire/ — The Law Offices of Howard G. Smith today reported that a securities class action lawsuit is pending against The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) on behalf of investors who acquired its securities from February 20, 2026 through August 4, 2026. The Chemours Company case, Darcy v. The Chemours Company et al., was filed on October 8, 2026 in the U.S. District Court District of Delaware (Wilmington) (Case No. 1:26-cv-01299).
Investors with losses on The Chemours Company securities can contact the Law Offices of Howard G. Smith about the Chemours Company lawsuit before the December 7, 2026 lead plaintiff deadline.
Key deadlines and dates for The Chemours Company investors
- Lead plaintiff deadline: December 7, 2026
- Class period: February 20, 2026 through August 4, 2026
- Complaint filed: October 8, 2026
What happened?
On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” Management further disclosed that “from the Q2 and Q3 perspective, there’s probably about $65 million of aftermarket sales that you think realistically should have been allocated to more of this year.”
On this news, Chemours shares fell $3.34, or 18.63%, to close at $14.59 per share on August 5, 2026, thereby injuring investors.
What is the Chemours Company lawsuit about?
The Chemours Company securities lawsuit alleges that, between February 20, 2026 and August 4, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about The Chemours Company’s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and (4) as a result, defendants’ positive statements about The Chemours Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
“The lawsuit against The Chemours Company alleges that, among other things, the Company failed to tell investors that Defendants had materially overstated aftermarket demand for their Opteon products. The Chemours Company investors who bought during the class period may be able to pursue their losses, and the December 7, 2026 deadline is where that process begins,” said Howard G. Smith of The Law Offices of Howard G. Smith.
Next steps for The Chemours Company investors
The Chemours Company investors who suffered losses may contact The Law Offices of Howard G. Smith to learn about pursuing their claims.
Lead plaintiff motions in the Chemours Company class action are due to the Court by December 7, 2026. For more information, visit the firm’s website, email howardsmith@howardsmithlaw.com, or call (215) 638-4847.
If you purchased The Chemours Company securities during the class period, you may retain counsel of your choice, or you may take no action and remain an absent class member. No class has been certified in the Chemours Company case so far.
Common questions from The Chemours Company investors
Who is eligible? Investors who acquired The Chemours Company securities from February 20, 2026 through August 4, 2026 and suffered losses may qualify for the class in the Chemours Company shareholder lawsuit.
What is the deadline? Lead plaintiff motions in the Chemours Company case are due by December 7, 2026.
Can I recover without being lead plaintiff? Yes, The Chemours Company investors may take no action and remain absent class members.
Does it cost anything? The Law Offices of Howard G. Smith works on contingency, so investors pay no attorneys’ fees unless there is a recovery, and any fees require court approval.
About The Law Offices of Howard G. Smith
The Law Offices of Howard G. Smith has helped injured investors recover their money for more than 15 years. The firm prosecutes securities fraud, takeover, and derivative litigation against public companies and their officers, directors, and advisors in federal and state courts nationwide, and has helped clients recover hundreds of millions of dollars in losses. Clients speak directly with a lawyer, who will promptly answer any question.
Prior results do not guarantee a similar outcome.
Related links
- The Chemours Company case page, The Law Offices of Howard G. Smith
- Complaint: Darcy v. The Chemours Company et al., U.S. District Court District of Delaware (Wilmington)
- press release
- The Chemours Company SEC filings index, EDGAR
- The Law Offices of Howard G. Smith
Contact
Howard G. Smith
The Law Offices of Howard G. Smith
3070 Bristol Pike, Suite 112
Bensalem, PA 19020
Email: howardsmith@howardsmithlaw.com
Telephone: (215) 638-4847
www.howardsmithlaw.com
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View original content:SOURCE Law Offices of Howard G. Smith
